公开(公告)号：KR100439733B1

公开(公告)日：2004-07-12

申请号：KR1020020000516

申请日：2002-01-04

Applicant: 신풍제약주식회사

Inventor： 한신 ,  박우일 ,  이동원 ,  김세현

IPC: C07D215/14

Abstract: PURPOSE: Provided is (±)-2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinone-4-mono)propionic acid which is prepared through simplified processing steps at high yield and high purity. CONSTITUTION: 4-halomethyl-2(1H)-quinolinone(formula III) reacts with dialkyl 4-chlorobenzoylamino malonate(formula IV) in the presence of an inorganic base in an alcoholic solvent to prepare alkyl 2-(4-chlorobenzoylamino)-2-(alkoxycarbonyl)-3-(2(1H)-quinolinone-4-mono)propionate(formula II) as an intermediate. It selectively suffers decarboxylation and hydrolysis using an acids mixture wherein acetic acid is mixed with other acids in a volume ratio of 1:0.3-10.2, thereby preparing the (±)-2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinone-4-mono)propionic acid(formula I). In the formulas, R is C1-6 alkyl group, and X1 is halogen.

Abstract translation: 目的：提供通过简单的加工步骤以高收率和高纯度制备的（（±）） - 2-（4-氯苯甲酰氨基）-3-（2（1H） - 喹啉酮-4-单）丙酸。 结构式：4-卤代甲基-2（1H） - 喹啉酮（式III）与无水碱存在下在醇溶剂中与4-氯苯甲酰氨基丙二酸二烷基酯（式IV）反应，制得2-（4-氯苯甲酰氨基）-2 - （烷氧基羰基）-3-（2（1H） - 喹啉酮-4-酮）丙酸酯（式II）。 由此制备（±）-2-（4-氯苯甲酰基氨基）-3-（ 2（1H） - 喹啉酮-4-单）丙酸（式I）。 在通式中，R是C 1-6烷基，并且X 1是卤素。

公开(公告)号：KR1020000037954A

公开(公告)日：2000-07-05

申请号：KR1019980052783

申请日：1998-12-03

Applicant: 신풍제약주식회사

Inventor： 한신 ,  박우일 ,  이상민 ,  이재욱

IPC: C07C229/40

Abstract: PURPOSE: Provided is a process for producing a £2-(2,6-dichloroanilino)phenyl|acetoxy acetate (aceclofenac) being used for an antipyretic, an analgesic in a high purity and yield, which is an economical and safe process. CONSTITUTION: A aceclofenac (formula 1) is produced by hydrolyzing an ester of a 2,2,2-trihaloethyl ester £2-(2,6-dichloroanilino)phenyl|acetoxy acetate (formula 2) having two esters with Zn or Zn-Cu catalyst in a formic acid, an acetic acid or a trifluoro acetate at 30-60°C for 3-8 hrs. The compound (formula 2) is produced by reacting a sodium or potassium £2-(2,6-dichloroanilino)phenyl| acetate (diclofenac) and a trihaloethyl halo acetate in an equivalent ratio of 1:1.1-1.5 in a dimethyl formamide or a dimethyl sulfoxide at 30-50°C. In the formula, X is a halogen.

Abstract translation: 目的：提供一种用于解热的2-（2,6-二氯苯胺基）苯基|乙酰氧基乙酸酯（醋氯芬酸），高纯度和高产率的止痛剂的方法，这是一种经济且安全的方法。 组成：通过水解具有两个酯的2,2,2-三卤代乙基酯（2-（2,6-二氯苯胺基）苯基|乙酰氧基乙酸酯（式2））的酯来制备醋氯芬酸（式1），其具有Zn或Zn- Cu催化剂在甲酸，乙酸或三氟乙酸酯中在30-60℃下反应3-8小时。 化合物（式2）通过使2-或2,6-二（2,6-二氯苯胺基）苯基钠钠或钾反应来制备 乙酸酯（双氯芬酸）和三卤代乙酸卤乙酸酯，其当量比为1:1.1-1.5，在二甲基甲酰胺或二甲基亚砜中，在30-50℃。 在该式中，X是卤素。

公开(公告)号：KR1020030059961A

公开(公告)日：2003-07-12

申请号：KR1020020000516

申请日：2002-01-04

Applicant: 신풍제약주식회사

Inventor： 한신 ,  박우일 ,  이동원 ,  김세현

IPC: C07D215/14

Abstract: PURPOSE: Provided is (±)-2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinone-4-mono)propionic acid which is prepared through simplified processing steps at high yield and high purity. CONSTITUTION: 4-halomethyl-2(1H)-quinolinone(formula III) reacts with dialkyl 4-chlorobenzoylamino malonate(formula IV) in the presence of an inorganic base in an alcoholic solvent to prepare alkyl 2-(4-chlorobenzoylamino)-2-(alkoxycarbonyl)-3-(2(1H)-quinolinone-4-mono)propionate(formula II) as an intermediate. It selectively suffers decarboxylation and hydrolysis using an acids mixture wherein acetic acid is mixed with other acids in a volume ratio of 1:0.3-10.2, thereby preparing the (±)-2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinone-4-mono)propionic acid(formula I). In the formulas, R is C1-6 alkyl group, and X1 is halogen.

Abstract translation: 目的：提供（±）-2-（4-氯苯甲酰氨基）-3-（2（1H） - 喹啉酮-4-单）丙酸，其通过简单的加工步骤以高产率和高纯度制备。 构成：4-卤代甲基-2（1H） - 喹啉酮（式III）在无水碱存在下在醇溶剂中与4-氯苯甲酰基氨基丙二酸二烷基酯（式Ⅳ）反应制备2-（4-氯苯甲酰氨基）-2 - （烷氧基羰基）-3-（2（1H） - 喹啉酮-4-单）丙酸酯（式II）作为中间体。 它选择性地使用酸混合物进行脱羧和水解，其中乙酸与体积比为1:0.3-10.2的其它酸混合，从而制备（±）-2-（4-氯苯甲酰氨基）-3-（2（1H， ） - 喹啉酮-4-单）丙酸（式I）。 式中，R为C1-6烷基，X1为卤素。

公开(公告)号：KR100354271B1

公开(公告)日：2002-09-28

申请号：KR1020000005071

申请日：2000-02-02

Applicant: 신풍제약주식회사

Inventor： 한신 ,  박우일 ,  강신철

IPC: C07C229/00

Abstract: 본 발명은 해열제, 골관절염 및 류마티스관절염 등의 관절질환과 각종 통증에 우수한 치료 효과를 나타내는 소염진통제로 널리 알려져 있는 화학식 1의 화합물[관용명:아세클로페낙(Aceclofenac)]의 신규 제조방법 및 그 제조 과정에서 중간체로 사용되는 화학식 2의 화합물 및 그의 제조방법에 관한 것이다:


상기식에서, R
1 은 C
1-4 알킬렌이고 R
2 는 C
1-4 알킬이다.
본 발명은 매우 저렴하고 사용이 편리한 산(acid)을 사용하여 선택적으로 가수분해시킴으로써 고수율 및 고순도의 화학식 1의 아세클로페낙을 간편하게 제조할 수 있다.

公开(公告)号：KR1020000003837A

公开(公告)日：2000-01-25

申请号：KR1019980025129

申请日：1998-06-29

Applicant: 신풍제약주식회사

Inventor： 한신 ,  조일환 ,  황의진 ,  이철규 ,  신장식

IPC: A61K31/14

CPC classification number: A61K31/661 ,  A61K45/06 ,  A61K2300/00 ,  Y10S514/885

Abstract: PURPOSE: An immune enhancer is provided to be used as an antibiotic and an anti-cancer medicine separately or mixed with another ingredient. CONSTITUTION: An immune enhancer containing a lombricine as an effective ingredient activates an immuno-cell of an organism for having an effect of enhancing an immune of the organism. The immune enhancer may be used as an antibiotic and an anti-cancer medicine separately or by mixed with other antibiotic or anti-cancer medicine for minimizing a virulence and maximizing an effect.

Abstract translation: 目的：提供免疫增强剂，用作抗生素和抗癌药物，或与其他成分混合使用。 构成：含有作为有效成分的洛米奇的免疫增强剂激活生物体的免疫细胞，以增强生物体的免疫作用。 免疫增强剂可以分别用作抗生素和抗癌药物，也可以与其它抗生素或抗癌药混合使用，以使毒性最小化并使效果最大化。

公开(公告)号：KR100439731B1

公开(公告)日：2004-07-12

申请号：KR1020010023645

申请日：2001-05-02

Applicant: 신풍제약주식회사

Inventor： 조승열 ,  채종일 ,  홍성태 ,  한신 ,  조일환

IPC: G01N33/53

Abstract: 본 발명은 간흡충, 폐흡충, 유구낭미충 및 고충(Sparganum) 감염증을 동시에 진단할 수 있는 효소면역진단(ELISA: Enzyme-Linked ImmunoSorbent Assay) 키트에 관한 것이다. 본 발명의 키트를 이용하면, 주요 조직내 기생충 감염증을 한 번에 규격화된 방법으로 간편하고 신속·정확하게 진단할 수 있다.

公开(公告)号：KR100399195B1

公开(公告)日：2003-09-26

申请号：KR1020010013859

申请日：2001-03-17

Applicant: 신풍제약주식회사

Inventor： 이성태 ,  한신 ,  박우일 ,  김형태

IPC: C07D501/12

Abstract: PURPOSE: Provided is a process for preparing amorphous form of cefuroxime axetil, thereby producing amorphous form of cefuroxime axetil, which is excellent in elution in a living body and has stability, in high yield and purity. CONSTITUTION: The amorphous cefuroxime axetil represented by the formula(1) is manufactured by the steps of: dissolving cefuroxime axetil in a polar organic solvent; passing CO2 gas therethrough; and adding a water soluble solution containing inorganic salts to precipitate amorphous cefuroxime axetil.

Abstract translation: 用途：提供一种制备无定形头孢呋辛酯的方法，由此制得无定形形式的头孢呋辛酯，其在生物体中洗脱性能优异，并且具有稳定性，高产率和纯度。 构成：由式（1）表示的无定形头孢呋辛酯通过以下步骤制备：将头孢呋辛酯溶解在极性有机溶剂中; 通过二氧化碳气体; 并加入含有无机盐的水溶性溶液以沉淀无定形头孢呋辛酯。

公开(公告)号：KR1020020084850A

公开(公告)日：2002-11-13

申请号：KR1020010023645

申请日：2001-05-02

Applicant: 신풍제약주식회사

Inventor： 조승열 ,  채종일 ,  홍성태 ,  한신 ,  조일환

IPC: G01N33/53

Abstract: PURPOSE: An enzyme-linked immunosorbent assay kit of Clonorchis sinensis., Paragonimus westermani, Cysticerus cellulosae and Sparganum infection syndrome is provided, thereby rapidly and correctly diagnosing the infection of main tissues with parasites. CONSTITUTION: The enzyme-linked immunosorbent assay kit of Clonorchis sinensis., Paragonimus westermani, Cysticerus cellulosae and Sparganum infection syndrome comprises a multi-well microplate or strip containing antigens of Clonorchis sinensis. Paragonimus westermani, Cysticerus cellulosae and Sparganum; a human serum which doesn't react with the antigens of Clonorchis sinensis. Paragonimus westermani, Cysticerus cellulosae and Sparganum as a negative standard serum; and a human serum which specifically and independently reacts with the antigens of Clonorchis sinensis., Paragonimus westermani, Cysticerus cellulosae and Sparganum as a positive standard serum.

Abstract translation: 目的：提供中华支气管炎，Paragonimus westermani，囊性囊性囊炎和Sparganum感染综合征的酶联免疫吸附测定试剂盒，从而快速正确地诊断主要组织与寄生虫的感染。 构成：Clonorchis sinensis，Paragonimus westermani，Cysticerus cellulosae和Sparganum感染综合征的酶联免疫吸附测定试剂盒包括含有Clonorchis sinensis抗原的多孔微孔板或条带。 Paragonimus westermani，Cysticerus cellulosae和Sparganum; 一种不与中华支原体抗原反应的人血清。 Paragonimus westermani，Cysticerus cellulosae和Sparganum作为阴性标准血清; 以及与Clonorchis sinensis，Paragonimus westermani，Cysticerus cellulosae和Sparganum的抗原作为阳性标准血清特异性和独立地反应的人血清。

公开(公告)号：KR1020020073918A

公开(公告)日：2002-09-28

申请号：KR1020010013859

申请日：2001-03-17

Applicant: 신풍제약주식회사

Inventor： 이성태 ,  한신 ,  박우일 ,  김형태

IPC: C07D501/12

Abstract: PURPOSE: Provided is a process for preparing amorphous form of cefuroxime axetil, thereby producing amorphous form of cefuroxime axetil, which is excellent in elution in a living body and has stability, in high yield and purity. CONSTITUTION: The amorphous cefuroxime axetil represented by the formula(1) is manufactured by the steps of: dissolving cefuroxime axetil in a polar organic solvent; passing CO2 gas therethrough; and adding a water soluble solution containing inorganic salts to precipitate amorphous cefuroxime axetil.

Abstract translation: 目的：提供头孢呋辛酯无定形形式的方法，由此生产无机形式的头孢呋辛酯，其在生物体中的洗脱性优异且稳定性高，产率高，纯度高。 构成：由式（1）表示的无定形头孢呋辛酯通过以下步骤制造：将头孢呋辛酯在极性有机溶剂中溶解; 使二氧化碳气体通过; 并加入含有无机盐的水溶性溶液以沉淀无定形头孢呋辛酯。

公开(公告)号：KR1020020046407A

公开(公告)日：2002-06-21

申请号：KR1020000076298

申请日：2000-12-14

Applicant: 신풍제약주식회사

Inventor： 이성태 ,  한신 ,  박우일 ,  주정철 ,  이철규 ,  김혜선

IPC: A61K9/08

CPC classification number: A61K9/0019 ,  A61K31/192 ,  A61K47/02

Abstract: PURPOSE: Provided is a pharmaceutical composition for intramuscular injection containing loxoprofen having excellent anti-inflammatory effects, as an active ingredient, and its pharmaceutically acceptable salts. CONSTITUTION: The pharmaceutical composition for intramuscular injection contains loxoprofen represented by the formula(1) or its pharmaceutically acceptable salts. It is manufactured by dissolving loxoprofen or its pharmaceutically acceptable salt, a stabilizing agent or solution adjuvant in water for injection then sterilizing it.

Abstract translation: 目的：提供含有作为活性成分的优良抗炎作用的洛索丙芬及其药学上可接受的盐的肌内注射用药物组合物。 构成：用于肌内注射的药物组合物含有由式（1）表示的洛索洛芬或其药学上可接受的盐。 它是通过将洛索洛芬或其药学上可接受的盐，稳定剂或溶液佐剂溶解在水中，然后对其进行消毒而制造的。